TGA proposes over-the-counter sales of CBD products – Small Caps

In a move that would appear to enthuse the ASX-listed cannabis stocks, the Therapeutic Goods Administration (TGA) has announced an interim decision to reclassify cannabidiol (CBD) products so they can be purchased over the counter at pharmacies.
The TGAs provisional ruling entails the down-scheduling of low dose CBD products from Schedule 4 to Schedule 3 of the Poisons Standard. This means companies can apply to register their applicable products to be available through a pharmacist, without th…

Click here to view the original article.